ReviewAnnals of translational medicine2019
Postobstructive pneumonia in lung cancer.
Review in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Stage-dependent prognostic value of clinical and pathological T staging in resected lung adenocarcinoma: a multicenter cohort study.BMC cancer · 2026Observational
- Value of [European journal of nuclear medicine and molecular imaging · 2026Article
- Malignancy Presenting As Recurrent Empyema: A Report of Two Cases and a Systematic Review.Cureus · 2026Article
- Trends in cause of death among patients with non-small cell lung cancer in the United States from 2000 to 2021: a SEER-based study.BMC public health · 2026Article
- Disentangling Links Between Lung Cancer and Infectious Pneumonia via Real-World Data and Integrative Genomics.Human mutation · 2026Article
- Review
- Prognostic Impact of Infectious Agents After Definitive Treatment in Non-Small Cell Lung Cancer.Cancers · 2025Article
- The impact of bronchoalveolar lavage fluid metagenomics next-generation sequencing on the diagnosis and management of patients with suspected pulmonary infection.Frontiers in cellular and infection microbiology · 2025Article
- Advances in diagnosis and treatment of lung cancer-associated obstructive pneumonia and lung abscess: synergistic strategies for infection control and antitumor therapy.Frontiers in cellular and infection microbiology · 2025Review
- Clinical characteristics and risk factors of late-stage lung adenocarcinoma patients with bacterial pulmonary infection and its relationship with cellular immune function.Frontiers in immunology · 2025Article
- Descriptors and factors affecting patients' symptom experiences for symptom self-management throughout palliative radiotherapy for advanced lung cancer: A systematic review.Asia-Pacific journal of oncology nursing · 2024Review
- Why do patients with cancer die?Nature reviews. Cancer · 2024Review
- Activity of zinc oxide and zinc borate nanoparticles against resistant bacteria in an experimental lung cancer model.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Enhancing Immune Response in Non-Small-Cell Lung Cancer Patients: Impact of the 13-Valent Pneumococcal Conjugate Vaccine.Journal of clinical medicine · 2024Article
- Value of [European radiology · 2024Article
- A non-enhanced CT-based deep learning diagnostic system for COVID-19 infection at high risk among lung cancer patients.Frontiers in medicine · 2024Article
- CT Characteristics and Clinical Findings of Bronchopneumonia Caused by Pepper Aspiration.International journal of general medicine · 2024Article
- Article
- Empyema caused byFrontiers in medicine · 2023Article
- Spatial meta-transcriptomics reveal associations of intratumor bacteria burden with lung cancer cells showing a distinct oncogenic signature.Journal for immunotherapy of cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postobstructive pneumonia can complicate lung cancer, particularly in more advanced stages of the disease, producing significant clinical decline and a poorer prognosis. It can lead to complications such as empyema, lung abscess and fistula formation. Postobstructive pneumonia can also be the first manifestation of an underlying malignancy. There are multiple challenges in the management of these patients. Recognition and treatment of this entity can be complex and includes the use of imaging, administration of broad-spectrum antibiotics to cover the wide variety of microorganisms involved and the use of different interventional modalities to relieve the obstruction. Existing literature on postobstructive pneumonia is scarce. In this article, we review the pathophysiology, different diagnostic methods and the therapeutic options to treat this condition. The utility and efficacy of the various modalities that are currently available in clinical practice to the interventional pulmonologist are described in some detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.